JP5753382B2 - 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ - Google Patents

修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ Download PDF

Info

Publication number
JP5753382B2
JP5753382B2 JP2010531606A JP2010531606A JP5753382B2 JP 5753382 B2 JP5753382 B2 JP 5753382B2 JP 2010531606 A JP2010531606 A JP 2010531606A JP 2010531606 A JP2010531606 A JP 2010531606A JP 5753382 B2 JP5753382 B2 JP 5753382B2
Authority
JP
Japan
Prior art keywords
orn
group
cancer
triphosphate
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010531606A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502979A (ja
JP2011502979A5 (enExample
Inventor
デベラク，ハラルト
ウルマン，オイゲン
Original Assignee
アディウティーダ ファーマシューティカルズ ゲーエムベーハー
アディウティーダ ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40626260&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5753382(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アディウティーダ ファーマシューティカルズ ゲーエムベーハー, アディウティーダ ファーマシューティカルズ ゲーエムベーハー filed Critical アディウティーダ ファーマシューティカルズ ゲーエムベーハー
Publication of JP2011502979A publication Critical patent/JP2011502979A/ja
Publication of JP2011502979A5 publication Critical patent/JP2011502979A5/ja
Application granted granted Critical
Publication of JP5753382B2 publication Critical patent/JP5753382B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
JP2010531606A 2007-11-06 2008-10-30 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ Expired - Fee Related JP5753382B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US204907P 2007-11-06 2007-11-06
US61/002,049 2007-11-06
PCT/IB2008/002940 WO2009060281A2 (en) 2007-11-06 2008-10-30 Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties

Publications (3)

Publication Number Publication Date
JP2011502979A JP2011502979A (ja) 2011-01-27
JP2011502979A5 JP2011502979A5 (enExample) 2015-02-19
JP5753382B2 true JP5753382B2 (ja) 2015-07-22

Family

ID=40626260

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010531606A Expired - Fee Related JP5753382B2 (ja) 2007-11-06 2008-10-30 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ

Country Status (10)

Country Link
US (2) US8349812B2 (enExample)
EP (1) EP2207787B1 (enExample)
JP (1) JP5753382B2 (enExample)
AU (1) AU2008326187B2 (enExample)
CA (1) CA2704853C (enExample)
DK (1) DK2207787T3 (enExample)
ES (1) ES2530215T3 (enExample)
HR (1) HRP20150131T1 (enExample)
PT (1) PT2207787E (enExample)
WO (1) WO2009060281A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
EP1631576A4 (en) * 2003-06-11 2010-08-25 Idera Pharmaceuticals Inc STABILIZED IMMUNOMODULATION OLIGONUCLEOTIDES
CA2536139A1 (en) * 2003-09-25 2005-04-07 Coley Pharmaceutical Group, Inc. Nucleic acid-lipophilic conjugates
DK2056845T3 (da) 2006-08-08 2017-11-27 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur og anvendelse af 5'-phosphat-oligonukleotider
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
WO2012079115A1 (en) * 2010-12-14 2012-06-21 Commonwealth Scientific And Industrial Research Organisation Immunostimulatory oligonucleotides
EP2508530A1 (en) * 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US20140287023A1 (en) * 2013-02-11 2014-09-25 Mcgill University 5'-triphosphate oligoribonucleotides
US9861574B2 (en) 2013-04-09 2018-01-09 Duke University 2-fluoro-modified RNAs as immunostimulators
KR102755601B1 (ko) 2015-10-14 2025-01-17 바이오-패쓰 홀딩스 인크. 리포좀 제제를 위한 p-에톡시 핵산
CA3034637A1 (en) 2016-09-16 2018-03-22 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
WO2018172546A1 (en) 2017-03-24 2018-09-27 Rigontec Gmbh Method for designing rig-i ligands
MX2019011824A (es) 2017-04-03 2020-01-09 Univ Duke Composiciones y métodos de inducción diferencial de la muerte celular y de la expresión del interferón.
CA3058018A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
EP3612160A4 (en) 2017-04-19 2021-01-20 Bio-Path Holdings, Inc. P-ETHOXY NUCLEIC ACIDS TO INHIBIT BCL2
WO2020260547A1 (en) 2019-06-27 2020-12-30 Rigontec Gmbh Design method for optimized rig-i ligands
US20230348903A1 (en) * 2020-05-19 2023-11-02 Hudson Institute of Medical Research Oligonucleotides
WO2025032348A1 (en) * 2023-08-10 2025-02-13 Harness Therapeutics Limited Functional nucleic acid

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3534017A (en) 1967-03-14 1970-10-13 Kyowa Hakko Kogyo Kk Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates
FR1566530A (enExample) 1967-03-14 1969-05-09
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
ATE75483T1 (de) 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
DE19935303A1 (de) * 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
US6268790B1 (en) 2000-03-24 2001-07-31 Trw Inc. Anti-theft method and apparatus
WO2003008432A1 (en) 2001-07-16 2003-01-30 Isis Pharmaceuticals, Inc. Process for the preparation of alpha modified nucleoside triphosphates and compounds therefrom
RU2004128943A (ru) 2002-02-28 2005-04-20 Байота, Инк. (Us) Средства, имитирующие нуклеотиды, и их пролекарственные формы
EP1499187B1 (en) * 2002-04-04 2015-06-17 Zoetis Belgium S.A. Immunostimulatory g,u-containing oligoribonucleotides
CA2555390C (en) * 2004-02-19 2014-08-05 Coley Pharmaceutical Group, Inc. Immunostimulatory viral rna oligonucleotides
WO2006063072A2 (en) * 2004-12-08 2006-06-15 3M Innovative Properties Company Immunomodulatory compositions, combinations and methods
US20060178334A1 (en) * 2005-02-04 2006-08-10 City Of Hope Double-stranded and single-stranded RNA molecules with 5 ' triphosphates and their use for inducing interferon
US8076068B2 (en) 2005-09-14 2011-12-13 Gunther Hartmann Method for determining immunostimulatory activity of RNA oligonucleotides
EA200800943A1 (ru) * 2005-09-27 2008-12-30 Коли Фармасьютикал Гмбх Модуляция tlr-опосредуемых иммунных ответов с использованием олигонуклеотидов-адаптеров
EP1937812A2 (en) * 2005-10-12 2008-07-02 Cancer Research Technology Limited Methods and compositions for treating immune disorders
JP5473336B2 (ja) * 2006-02-15 2014-04-16 アディウタイド・ファーマスーティカルズ・ゲーエムベーハー オリゴヌクレオチドの処方に関する組成物および方法
JP5761911B2 (ja) * 2006-04-07 2015-08-12 イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｔｌｒ７およびｔｌｒ８に対する安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物
EP1920775B1 (en) 2006-10-10 2012-12-19 Gunther Prof. Dr. Hartmann 5'Triphosphate oligonucleotide induces anti-viral response

Also Published As

Publication number Publication date
US20100260788A1 (en) 2010-10-14
AU2008326187A1 (en) 2009-05-14
EP2207787B1 (en) 2014-11-12
CA2704853C (en) 2017-08-15
ES2530215T3 (es) 2015-02-27
JP2011502979A (ja) 2011-01-27
EP2207787A2 (en) 2010-07-21
CA2704853A1 (en) 2009-05-14
US9156875B2 (en) 2015-10-13
US8349812B2 (en) 2013-01-08
AU2008326187B2 (en) 2014-12-04
DK2207787T3 (en) 2015-02-09
US20130164333A1 (en) 2013-06-27
HRP20150131T1 (hr) 2015-04-10
WO2009060281A2 (en) 2009-05-14
WO2009060281A3 (en) 2009-08-13
PT2207787E (pt) 2015-02-17

Similar Documents

Publication Publication Date Title
JP5753382B2 (ja) 修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ
JP2011502979A5 (enExample)
CN102517292B (zh) 免疫刺激性寡核糖核苷酸
JP5414961B2 (ja) 免疫刺激性核酸
US9186399B2 (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties
JP2006508693A5 (enExample)
EP2104738A2 (en) Oligoribonucleotides and uses thereof
JP5755827B2 (ja) 強化された免疫刺激活性を有するリン酸が修飾されたオリゴヌクレオチド類似体
AU2008288241B2 (en) RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
CN101331229B (zh) 免疫刺激性寡核糖核苷酸
HK1133043A (en) Oligoribonucleotides and uses thereof
HK1143741B (en) Rna sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles
HK1143314A (en) Immune stimulatory oligonucleotide analogs containing modified sugar moieties

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110725

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140905

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140912

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20141224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150428

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150522

R150 Certificate of patent or registration of utility model

Ref document number: 5753382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees